{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:52:25Z","timestamp":1761101545229,"version":"3.40.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Foundation Award"],"award-info":[{"award-number":["Foundation Award"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-21-0031455"],"award-info":[{"award-number":["G-21-0031455"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010564","name":"Academic Medical Organization of Southwestern Ontario","doi-asserted-by":"publisher","award":["INN21-011"],"award-info":[{"award-number":["INN21-011"]}],"id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40291-024-00768-0","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:19:42Z","timestamp":1738081182000},"page":"291-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Therapeutics in Development to Treat Hyperlipoproteinemia"],"prefix":"10.1007","volume":"29","author":[{"given":"Maud","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"768_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","volume":"43","author":"AJ Berberich","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43:611\u20133. https:\/\/doi.org\/10.1210\/endrev\/bnab037.","journal-title":"Endocr Rev"},{"key":"768_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/MOL.0000000000000631","volume":"30","author":"KR Feingold","year":"2019","unstructured":"Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Curr Opin Lipidol. 2019;30:388\u201394. https:\/\/doi.org\/10.1097\/MOL.0000000000000631.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","volume":"3","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a): seeing the forest through the trees. Curr Opin Lipidol. 2022;3:342\u201352. https:\/\/doi.org\/10.1097\/MOL.0000000000000855.","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"768_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/JAMACARDIO.2024.1882","volume":"9","author":"BJ Arsenault","year":"2024","unstructured":"Arsenault BJ, Loganath K, Girard A, Botezatu S, Zheng KH, Tzolos E, et al. Lipoprotein(a) and calcific aortic valve stenosis progression: a systematic review and meta-analysis. JAMA Cardiol. 2024;9(9):835\u201342. https:\/\/doi.org\/10.1001\/JAMACARDIO.2024.1882.","journal-title":"JAMA Cardiol."},{"key":"768_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MOL.0000000000000866","volume":"34","author":"SMT Hang","year":"2023","unstructured":"Hang SMT, Hegele RA, Berberich AJ. Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia. Curr Opin Lipidol. 2023;34:59\u201369. https:\/\/doi.org\/10.1097\/MOL.0000000000000866.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/MOL.0000000000000875","volume":"34","author":"OP Ganda","year":"2023","unstructured":"Ganda OP. Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease. Curr Opin Lipidol. 2023;34:105\u201313. https:\/\/doi.org\/10.1097\/MOL.0000000000000875.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/MOL.0000000000000897","volume":"34","author":"DJ McClintick","year":"2023","unstructured":"McClintick DJ, Giugliano RP. Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review. Curr Opin Lipidol. 2023;34:243\u201351. https:\/\/doi.org\/10.1097\/MOL.0000000000000897.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MOL.0000000000000849","volume":"33","author":"D Tramontano","year":"2022","unstructured":"Tramontano D, Bini S, D\u2019Erasmo L, Arca M. Recent apolipoprotein CIII trials. Curr Opin Lipidol. 2022;33:309\u201318. https:\/\/doi.org\/10.1097\/MOL.0000000000000849.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/MOL.0000000000000920","volume":"35","author":"DC Chan","year":"2024","unstructured":"Chan DC, Watts GF. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses? Curr Opin Lipidol. 2024;35:101\u20139. https:\/\/doi.org\/10.1097\/MOL.0000000000000920.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/eurheartj\/ehae068","volume":"45","author":"RA Hegele","year":"2024","unstructured":"Hegele RA. Inhibiting angiopoietin-like protein 3: clear skies or clouds on the horizon? Eur Heart J. 2024;45:722\u20134. https:\/\/doi.org\/10.1093\/eurheartj\/ehae068.","journal-title":"Eur Heart J"},{"key":"768_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"RS Rosenson","year":"2018","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018;72:314\u201329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.054.","journal-title":"J Am Coll Cardiol"},{"key":"768_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s11883-022-01057-z","volume":"24","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Gar\u00e7on D. Expanding biology of PCSK9: roles in atherosclerosis and beyond. Curr Atheroscler Rep. 2022;24:821\u201330. https:\/\/doi.org\/10.1007\/s11883-022-01057-z.","journal-title":"Curr Atheroscler Rep"},{"key":"768_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136. https:\/\/doi.org\/10.1038\/ng1161.","journal-title":"Nat Genet"},{"key":"768_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161\u20135. https:\/\/doi.org\/10.1038\/ng1509.","journal-title":"Nat Genet"},{"key":"768_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372. https:\/\/doi.org\/10.1056\/NEJMoa054013.","journal-title":"N Engl J Med"},{"key":"768_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.06.971","volume":"378","author":"R Marfella","year":"2023","unstructured":"Marfella R, Prattichizzo F, Sardu C, Paolisso P, D\u2019Onofrio N, Scisciola L, et al. Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis. 2023;378: 117180. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.06.971.","journal-title":"Atherosclerosis"},{"key":"768_CR17","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","volume":"37","author":"GJ Pearson","year":"2021","unstructured":"Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37:1129\u201350. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","journal-title":"Can J Cardiol"},{"issue":"7","key":"768_CR18","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/EURHEARTJ\/EHZ430","volume":"43","author":"P Guedeney","year":"2022","unstructured":"Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):e17-25. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ430.","journal-title":"Eur Heart J"},{"issue":"12","key":"768_CR19","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.cjca.2018.04.002","volume":"34","author":"RD Turgeon","year":"2018","unstructured":"Turgeon RD, Tsuyuki RT, Gyenes GT, Pearson GJ. Cardiovascular efficacy and safety of PCSK9 inhibitors: systematic review and meta-analysis including the ODYSSEY OUTCOMES Trial. Can J Cardiol. 2018;34(12):1600\u20135. https:\/\/doi.org\/10.1016\/j.cjca.2018.04.002.","journal-title":"Can J Cardiol"},{"key":"768_CR20","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","volume":"42","author":"E Bruckert","year":"2022","unstructured":"Bruckert E, Caprio S, Wiegman A, Charng MJ, Z\u00e1rate-Morales CA, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study. Arterioscler Thromb Vasc Biol. 2022;42:1447\u201357. https:\/\/doi.org\/10.1161\/ATVBAHA.122.317793.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"768_CR21","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1161\/ATVBAHA.123.320268","volume":"44","author":"FJ Raal","year":"2024","unstructured":"Raal FJ, Hegele RA, Ruzza A, L\u00f3pez JAG, Bhatia AK, Wu J, et al. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies. Arterioscler Thromb Vasc Biol. 2024;44:1156\u201364. https:\/\/doi.org\/10.1161\/ATVBAHA.123.320268.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"768_CR22","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","volume":"44","author":"M Cuchel","year":"2023","unstructured":"Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44:2277\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/ehad197.","journal-title":"Eur Heart J"},{"key":"768_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31083\/j.rcm2505190","volume":"25","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Hegele RA, Brown V, Bergeron J, Mackinnon ES, Mancini GBJ. Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease. Rev Cardiovasc Med. 2024;25:190. https:\/\/doi.org\/10.31083\/j.rcm2505190.","journal-title":"Rev Cardiovasc Med"},{"key":"768_CR24","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1316222.","journal-title":"N Engl J Med"},{"key":"768_CR25","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"15","key":"768_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, Atar D, Keech A, Kuder JF, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620.","journal-title":"Circulation"},{"key":"768_CR27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1501031.","journal-title":"N Engl J Med"},{"key":"768_CR28","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"768_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MOL.0000000000000877","volume":"34","author":"S Giordano","year":"2023","unstructured":"Giordano S, Polimeni A, Esposito G, Indolfi C, Spaccarotella C. Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent. Curr Opin Lipidol. 2023;34:133\u201340. https:\/\/doi.org\/10.1097\/MOL.0000000000000877.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR30","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa19138055","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa19138055.","journal-title":"N Engl J Med"},{"key":"768_CR31","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"768_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44:129\u201338. https:\/\/doi.org\/10.1093\/eurheartj\/ehac594.","journal-title":"Eur Heart J"},{"key":"768_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","volume":"149","author":"F Raal","year":"2024","unstructured":"Raal F, Durst R, Bi R, Talloczy Z, Maheux P, Lesogor A, ORION-5 Study Investigators, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149:354\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.063460.","journal-title":"Circulation"},{"key":"768_CR34","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, Blom D, De Vries BM, Kayikcioglu M, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44:4272\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehad596.","journal-title":"Eur Heart J"},{"key":"768_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.1659","author":"EQ Klug","year":"2024","unstructured":"Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, LIBERATE-HR Investigators, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024. https:\/\/doi.org\/10.1001\/jamacardio.2024.1659.","journal-title":"JAMA Cardiol."},{"key":"768_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/MOL.0000000000000805","volume":"33","author":"MN Whittaker","year":"2022","unstructured":"Whittaker MN, Musunuru K. Therapeutic application of genome editing in dyslipidemia. Curr Opin Lipidol. 2022;33:133\u20138. https:\/\/doi.org\/10.1097\/MOL.0000000000000805.","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"768_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/PCMEDI\/PBAB014","volume":"4","author":"W Liu","year":"2021","unstructured":"Liu W, Li L, Jiang J, Wu M, Lin P. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics. Precis Clin Med. 2021;4(3):179. https:\/\/doi.org\/10.1093\/PCMEDI\/PBAB014.","journal-title":"Precis Clin Med."},{"key":"768_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, Platt C, Vafai SB, Kathiresan S, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147:242\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062132.","journal-title":"Circulation"},{"key":"768_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11883-024-01193-8","volume":"26","author":"M Hermel","year":"2024","unstructured":"Hermel M, Chiou A, Minhas AMK, Inam M, Waldman CE, Youngblood E, et al. Highlights of cardiovascular disease prevention studies presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2024;26:119\u201331. https:\/\/doi.org\/10.1007\/s11883-024-01193-8.","journal-title":"Curr Atheroscler Rep"},{"key":"768_CR40","unstructured":"Verve Therapeutics. Verve Therapeutics announces pipeline progress and reports third quarter 2024 financial results. Available from: https:\/\/vervetx.gcs-web.com\/news-releases\/news-release-details\/verve-therapeutics-announces-pipeline-progress-and-reports-2. Accessed 3 Dec 2024."},{"key":"768_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"C Ballantyne","year":"2023","unstructured":"Ballantyne C, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81:1553\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"768_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","volume":"33","author":"MB Boffa","year":"2022","unstructured":"Boffa MB, Koschinsky ML. Understanding the ins and outs of lipoprotein (a) metabolism. Curr Opin Lipidol. 2022;33:185\u201392. https:\/\/doi.org\/10.1097\/MOL.0000000000000823.","journal-title":"Curr Opin Lipidol"},{"issue":"9","key":"768_CR43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/J.JACC.2022.06.019","volume":"80","author":"S Tsimikas","year":"2022","unstructured":"Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. J Am Coll Cardiol. 2022;80(9):934\u201346. https:\/\/doi.org\/10.1016\/J.JACC.2022.06.019.","journal-title":"J Am Coll Cardiol"},{"key":"768_CR44","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","volume":"42","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e48-60. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"768_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cjco.2023.09.018","volume":"6","author":"EO Jacob","year":"2023","unstructured":"Jacob EO, McIntyre AD, Wang J, Hegele RA. Lipoprotein(a) in familial hypercholesterolemia. CJC Open. 2023;6:40\u20136. https:\/\/doi.org\/10.1016\/j.cjco.2023.09.018.","journal-title":"CJC Open."},{"key":"768_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/MOL.0000000000000641","volume":"30","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Proprotein convertase subtilisin\/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye? Curr Opin Lipidol. 2019;30:428\u201337. https:\/\/doi.org\/10.1097\/MOL.0000000000000641.","journal-title":"Curr Opin Lipidol"},{"key":"768_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"key":"768_CR48","unstructured":"ClinicalTrials.gov. Assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04023552. Accessed 22 Jul 2024."},{"key":"768_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clinthera.2022.07.008","volume":"44","author":"W Sohn","year":"2022","unstructured":"Sohn W, Winkle P, Neutel J, Wu Y, Jabari F, Terrio C, et al. Pharmacokinetics, pharmacodynamics, and tolerability of olpasiran in healthy Japanese and non-Japanese participants: results from a phase I, single-dose, open-label study. Clin Ther. 2022;44:123\u201347. https:\/\/doi.org\/10.1016\/j.clinthera.2022.07.008.","journal-title":"Clin Ther"},{"key":"768_CR50","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2211023.","journal-title":"N Engl J Med"},{"key":"768_CR51","unstructured":"ClinicalTrials.gov. Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05581303. Accessed 6 Aug 2024."},{"key":"768_CR52","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330:2075\u201383. https:\/\/doi.org\/10.1001\/jama.2023.21835.","journal-title":"JAMA"},{"key":"768_CR53","unstructured":"ClinicalTrials.gov. A study of LY3819469 in participants with elevated lipoprotein(a) [Lp(a)]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05565742. Accessed 6 Aug 2024."},{"key":"768_CR54","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wolski K, Watts GF, Koren MJ, Fok H, Nicholls SJ, et al. Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial. JAMA. 2024;331:1534\u201343. https:\/\/doi.org\/10.1001\/jama.2024.4504.","journal-title":"JAMA"},{"issue":"23","key":"768_CR55","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/JAMA.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran: a small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial. JAMA. 2024;332(23):1992\u20132002. https:\/\/doi.org\/10.1001\/JAMA.2024.21957.","journal-title":"JAMA"},{"key":"768_CR56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","volume":"330","author":"SJ Nicholls","year":"2023","unstructured":"Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330:1042\u201353. https:\/\/doi.org\/10.1001\/jama.2023.16503.","journal-title":"JAMA"},{"key":"768_CR57","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2024.24017","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial. JAMA. 2024. https:\/\/doi.org\/10.1001\/JAMA.2024.24017.","journal-title":"JAMA"},{"issue":"1","key":"768_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99\u2013109c. https:\/\/doi.org\/10.1093\/eurheartj\/ehz785.","journal-title":"Eur Heart J"},{"issue":"1","key":"768_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"14","key":"768_CR60","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/eurheartj\/ehab890","volume":"43","author":"RA Hegele","year":"2022","unstructured":"Hegele RA. Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all? Eur Heart J. 2022;43(14):1413\u20135. https:\/\/doi.org\/10.1093\/eurheartj\/ehab890.","journal-title":"Eur Heart J"},{"issue":"1","key":"768_CR61","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1308027.","journal-title":"N Engl J Med"},{"key":"768_CR62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1715944.","journal-title":"N Engl J Med"},{"key":"768_CR63","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, COMPASS Study Group, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(21)00046-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"768_CR64","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2022.08.008","volume":"16","author":"EA Oral","year":"2022","unstructured":"Oral EA, Garg A, Tami J, Huang EA, O\u2019Dea LSL, Schmidt H, et al. Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study: volanesorsen in FPLD; the BROADEN Study. J Clin Lipidol. 2022;16:833\u201349. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.008.","journal-title":"J Clin Lipidol"},{"key":"768_CR65","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMc2306575","volume":"390","author":"VJ Alexander","year":"2024","unstructured":"Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, Gouni-Berthold I, et al. Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia. N Engl J Med. 2024;390:476\u20137.","journal-title":"N Engl J Med"},{"key":"768_CR66","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehab820.","journal-title":"Eur Heart J"},{"key":"768_CR67","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jacl.2022.06.005","volume":"16","author":"E Karwatowska-Prokopczuk","year":"2022","unstructured":"Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, Ballantyne CM, Shapiro MD, Moriarty PM, et al. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022;16:617\u201325. https:\/\/doi.org\/10.1016\/j.jacl.2022.06.005.","journal-title":"J Clin Lipidol"},{"key":"768_CR68","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390:1781\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2400201.","journal-title":"N Engl J Med"},{"key":"768_CR69","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390:1770\u201380.","journal-title":"N Engl J Med"},{"issue":"10","key":"768_CR70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2404143","volume":"391","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):899\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2404143.","journal-title":"N Engl J Med"},{"issue":"7","key":"768_CR71","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2024.0959.","journal-title":"JAMA Cardiol."},{"key":"768_CR72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409368","author":"GF Watts","year":"2024","unstructured":"Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409368.","journal-title":"N Engl J Med"},{"key":"768_CR73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"key":"768_CR74","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383:2307\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2031049.","journal-title":"N Engl J Med"},{"key":"768_CR75","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29:729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"key":"768_CR76","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41:3936\u201345.","journal-title":"Eur Heart J"},{"key":"768_CR77","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, Curto M, Ramos V, Jevne A, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377\u201386.","journal-title":"Circulation"},{"key":"768_CR78","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29:2216\u201323. https:\/\/doi.org\/10.1038\/s41591-023-02494-2.","journal-title":"Nat Med"},{"issue":"10","key":"768_CR79","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2404147.","journal-title":"N Engl J Med"},{"key":"768_CR80","doi-asserted-by":"publisher","first-page":"Suppl 2","DOI":"10.1093\/EURHEARTJ\/EHAD655.2521","volume":"44","author":"R Lee","year":"2023","unstructured":"Lee R, Denizio J, Mizoguchi T, Dutta C, Clendaniel V, Garrity R, et al. An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models. Eur Heart J. 2023. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD655.2521.","journal-title":"Eur Heart J"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00768-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00768-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:02:21Z","timestamp":1746734541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00768-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["768"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00768-0","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"type":"print","value":"1177-1062"},{"type":"electronic","value":"1179-2000"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"15 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Robert A. Hegele is supported by the Jacob J. Wolfe Distinguished Medical Research Chair, the Edith Schulich Vinet Research Chair, and the Martha G. Blackburn Chair in Cardiovascular Research. Robert A. Hegele holds operating grants from the Canadian Institutes of Health Research (Foundation award), the Heart and Stroke Foundation of Ontario (G-21-0031455), and the Academic Medical Association of Southwestern Ontario (INN21-011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maud Ahmad has no conflicts of interest that are directly relevant to the content of this article. Robert A. Hegele reports consulting fees from Acasti, Aegerion, Akcea\/Ionis, Amgen, Arrowhead, Boston Heart, HLS Therapeutics, Pfizer, Medison, Novartis, Regeneron, Sanofi, and Ultragenyx. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors designed the approach to the literature review, drafted the article, made revisions, and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}